Innovative Non-Invasive Diagnostics and Personalized Treatment Strategies for Endometriosis Through Advanced Multi-Omics and Ultrasound Integration (ENDO-NOVA)
Innovativa Icke-invasiva Diagnostiska Och Personliga Behandlingsstrategier för Endometrios Genom Avancerad Multi-omik Och Ultraljudsintegration
Endometriosis is a prevalent gynecological condition affecting approximately 10% of women of reproductive age worldwide. It presents with nonspecific but often severe symptoms, including chronic pelvic pain (in 70% of cases) and infertility (in up to 40% of cases), imposing significant physical, psychological, economic, and societal burdens. Despite its widespread occurrence, the exact etiology and pathogenesis of endometriosis remain unclear, and no definitive cure exists. Early diagnosis and management are crucial for improving patient outcomes; however, major diagnostic delays persist. Current imaging techniques such as transvaginal ultrasound (TVUS) examination and magnetic resonance imaging, along with biochemical markers lack sufficient specificity. Consequently, confirmation of diagnosis still requires surgical procedures under general anesthesia, i.e.
laparoscopy ("key-hole surgery") and tissue biopsy. This delay exacerbates the disease burden and healthcare costs, underscoring the urgent need for non-invasive, precise diagnostic strategies. This project proposes a multi-modal approach integrating advanced ultrasound imaging with novel biomarkers identified via comprehensive multi-omics analyses, including proteomics, transcriptomics, and immune profiling, of patient-derived endometrial organoids. It aims to understand the underlying mechanisms of reduced endometrial receptivity of embryos in patients with endometriosis. Additionally, we will explore personalized treatment strategies by utilizing patient-specific organoids for drug screening and evaluation of treatment response.
This project aims to develop a non-invasive diagnostic strategy by integrating:
- AI-enhanced TVUS for improved lesion detection.
- Multi-omics biomarker discovery through proteomics, transcriptomics, and immune profiling.
- Underpinning the mechanisms of reduced endometrial receptivity in endometriosis using an in vitro model of embryo-endometrium interaction.
- Endometrial organoid models to enable precision medicine-based drug testing. The development of a reliable noninvasive or minimally invasive diagnostic test-or a combination of tests-could revolutionize the diagnostic pathway by reducing delays, avoiding the need for surgery, and facilitating disease monitoring and treatment evaluation.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Stefhanie Romero Andersson, MD, PhD, MSc
- Numero di telefono: 0046707822742
- Email: stefhanie.romero.andersson@ki.se
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Women aged 18-45
- Understands and speaks the Swedish language
- Suspected or confirmed endometriosis
Exclusion Criteria:
- Do not have a uterus
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
1
Never had treatment
|
Diagnosis using AI-enhanced transvaginal ultrasound, multi-omics, and organoids
|
|
2
Ongoing treatment
|
Diagnosis using AI-enhanced transvaginal ultrasound, multi-omics, and organoids
|
|
3
No actual treatment (has had treatment before)
|
Diagnosis using AI-enhanced transvaginal ultrasound, multi-omics, and organoids
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diagnostic accuracy of the combined AI-assisted transvaginal ultrasound and multi-omics biomarker model for detection of endometriosis
Lasso di tempo: At baseline diagnostic evaluation
|
Sensitivity and specificity of a combined diagnostic model integrating AI-assisted interpretation of transvaginal ultrasound images with plasma, saliva, urine, and endometrial-derived biomarkers for the detection of endometriosis, using laparoscopic diagnosis with or without histological confirmation as the reference standard.
|
At baseline diagnostic evaluation
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diagnostic accuracy of AI-assisted transvaginal ultrasound alone
Lasso di tempo: Baseline
|
To evaluate the performance of AI-assisted transvaginal ultrasound (TVUS) for detection and classification of endometriosis lesions.
|
Baseline
|
|
Diagnostic performance of plasma and endometrial biomarker panel
Lasso di tempo: Baseline sample collection
|
To assess the ability of plasma and endometrial-derived biomarkers to detect endometriosis, disease stage, and correlate to clinical symptoms.
|
Baseline sample collection
|
|
Implantation rate in in vitro endometrial models
Lasso di tempo: Periprocedural/ During in vitro culture period (e.g., up to 5-10 days)
|
To compare the attachment rate of embryo-derived or stem cell-derived embryonic structures (blastoids) to endometrial tissue from women with and without endometriosis.
|
Periprocedural/ During in vitro culture period (e.g., up to 5-10 days)
|
|
Molecular characteristics associated with embryo/blastoid attachment
Lasso di tempo: Periprocedural/During in vitro experiments
|
To evaluate transcriptomic and hormonal differences between successfully and unsuccessfully attaching embryos or blastoids.
|
Periprocedural/During in vitro experiments
|
|
Organoid drug response variability and association with disease characteristics
Lasso di tempo: At baseline sample collection and through study completion (around 3 years)
|
To evaluate variability in response to hormonal and immune-targeted therapies in organoids and association with disease severity.
|
At baseline sample collection and through study completion (around 3 years)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: Ronak Perot, MD, Region Stockholm
- Cattedra di studio: Lars Henningsohn, MD,Prof, Karolinska Institutet
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- DNR 2025-03336-01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Non-invasive diagnosis of endometriosis
-
Cuiling FengLinfen Central Hospital; Zhuhai Hospital of Integrated Traditional Chinese and... e altri collaboratoriNon ancora reclutamento